XPH News and Press, SPDR S&P Pharmaceuticals From 07/17/23

2023-07-17 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-07-16 10:24:01 ET Summary XPH’s consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 2030, and narrow revenue stream expected from...

2023-07-11 21:25:00 ET Summary Health care’s innovation-driven growth and inherent resilience makes it a natural fit for dividend growth investors, according to Franklin Equity Group. Technology in health care has historically driven a broad range of innovation, from the do...

2023-07-09 12:00:00 ET Despite a disappointing start to 2023, the healthcare sector has several promising industries waiting to outperform this year, Goldman Sachs said in a recent report after the bank concluded its annual healthcare conference in Dana Point, California, last month. Th...

2023-07-08 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-06-21 07:20:12 ET SPDR S&P Pharmaceuticals ETF ( XPH ) - $0.1235 . 30-Day SEC Yield of 1.14% as of Jun. 15. Payable Jun 23; for shareholders of record Jun 21; ex-div Jun 20. For further details see: SPDR S&P Pharmaceuticals ETF declares quarterly dis...

2023-06-09 07:36:00 ET Summary Healthcare companies are beginning to explore how artificial intelligence might unlock efficiencies for patients and medical systems. Companies that put cash to work by investing in innovation are signaling efforts to secure consistent long-term prof...

2023-06-09 02:00:00 ET Summary Recent clinical trial success for the second significant, disease-modifying drug to treat Alzheimer’s is a critical milestone and a positive sign for the future of neuroscience. Technological advancements, particularly artificial intelligence ...

2023-05-29 10:57:56 ET Summary iShares Select Dividend ETF offers high quarterly income checks, steady income growth, and broad diversification. Weak 3-month price change could be opening a smart buy entry for new capital. DVY could be a core position in an income-oriented por...

2023-05-29 09:00:00 ET Summary PFE's historical stock performance remains mediocre compared to its pharmaceutical peers, even after adjusting for dividends. Combined with its decelerating COVID-19 portfolio and $22B worth of annualized patent cliff from 2025 onwards, we are not su...